Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it is presenting new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, November 13-16, 2018.
Two posters are presented in the late-breaking abstract session. Late-breaking abstracts are selected to highlight novel and potentially practice-changing studies, e.g. ground-breaking and unique data that would not otherwise have been presented at the conference. These posters are showing data on the anticancer effects of BAL101553 in combination with eribulin or gemcitabine, which are approved anticancer drugs for the treatment of advanced metastatic breast cancer and pancreatic cancer, respectively.
Dr. Marc Engelhardt, Chief Medical Officer, said: "We are pleased that our two abstracts have been selected as late-breaking. The preclinical data show well-tolerated profound synergistic anticancer effects of BAL101553 in combination with the well-established cancer drugs eribulin and gemcitabine, suggesting that such combinations could also be advantageous for patients with advanced metastatic breast cancer and pancreatic cancer."
The first poster shows a highly synergistic anticancer effect of the combination of BAL101553 with eribulin in in-vitro cancer models. Moreover, such combinations are shown to be associated with a dose-dependent significant increase of complete regressions, i.e. cures of up to 80% in an animal model of triple-negative breast cancer.
The second poster shows that the combination of BAL101553 with gemcitabine led to complete regression in an animal model of pancreatic cancer (PDAC), compared to tumor size stabilization (stasis) with gemcitabine alone. Upon treatment cessation, tumors in the gemcitabine monotherapy group regrew while 40-80% of the animals in the combination groups remained in complete regression and were confirmed as cures.
A third poster presented at the symposium includes data generated in collaboration with the research group of Prof. Diane Braguer of the Aix-Marseille University, France. The data show that BAL101553 significantly increases the survival duration in an animal model of glioblastoma (brain cancer) after long-term oral administration. The survival benefit was largest in tumors expressing the EB-1 protein, which has previously been identified as a potential predictive biomarker of tumor response to BAL101553.1 In addition, the data show that BAL101553 counteracts the formation of tumor vessels (angiogenesis), thus cutting off the tumor from blood and nutrition supply and potentially adding to the direct anticancer effect.
Presentation on BAL101553 at the EORTC-NCI-AACR symposium
BAL101553, a novel microtubule-targeting tumor checkpoint controller, in combination with eribulin leads to increased cures in a TNBC xenograft model. N. Forster-Gros, F. Bachmann, P. McSheehy, H. A. Lane. Tuesday, November 13 to Friday, November 16, 2018, 10:00 a.m. - 5:30 p.m., Exhibition Hall, Poster Board 214, Late-Breaking Abstract 11
BAL101553, a novel microtubule-targeting tumor checkpoint controller, synergizes with gemcitabine providing cures in a PDX-pancreatic model. H. Lane, P. McSheehy, F. Bachmann. Tuesday, November 13 to Friday, November 16, 2018, 10:00 a.m. - 5:30 p.m., Exhibition Hall, Poster Board 216, Late-Breaking Abstract 16
EB1-dependent long survival of glioblastoma cancer stem-like cell tumor-bearing mice after daily oral treatment with the novel Tumor Checkpoint Controller BAL101553. R. Bergès, A. Tchoghandjian, A. Sergé, D. Figarella-Branger, F. Bachmann, H. Lane, D. Braguer. Wednesday, November 14, 2018, 10:00 a.m. - 5:30 p.m.; Exhibition Hall, Poster Board 017
For further information please visit www.ecco-org.eu/Events/ENA2018.